HER2 positive breast cancer

40 trials 14 recruiting MedDRA PT
40 Registered trials
14 Recruiting
25 Unique sponsors
47 Unique IMPs
28 Commercial trials
Drug classes (ATC)
— ATC code not specified 20
L Oncology (ATC L) 19
V Various (ATC V) 1
A Gastroenterology (ATC A) 3
H Endocrinology (ATC H) 2
N Neurology/Psychiatry (ATC N) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 20 substances
Antibody-drug conjugate (ADC) 3 substances
Monoclonal antibody (tumor, humanized) 3 substances
Colony-stimulating factor 3 substances
Corticosteroid 3 substances
Platinum compound 2 substances
Taxane 2 substances
CDK inhibitor 2 substances
Antimetabolite 2 substances
Checkpoint inhibitor (PD-L1) 1 substance
Kinase inhibitor 1 substance
Supportive / rescue 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Alkylating agent 1 substance
Anthracycline 1 substance
Analgesic / antipyretic 1 substance
Phase III: 12 Phase II/III: 1 Phase II: 12 Phase I/II: 6 Phase III/IV: 1 Phase I: 5 Phase I (Other): 3

Filter these 40 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 40 trials

Phase III

12 trials
  • Aprogen Inc. Commercial
    IMP not specified
    2023-506975-83-00 2 countries n=66
    Ended
  • Daiichi Sankyo Inc. Commercial
    TRASTUZUMAB DERUXTECAN
    2023-506330-73-00 4 countries 2024 n=64
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    TRASTUZUMAB DERUXTECAN; TRASTUZUMAB EMTANSINE
    2023-507961-24-00 13 countries 2021 n=1,124
    Ended
  • Daiichi Sankyo Inc. Commercial
    TRASTUZUMAB DERUXTECAN; TRASTUZUMAB EMTANSINE
    2024-511204-16-00 4 countries 2019 n=63
    Ended
  • F. Hoffmann-La Roche AG Commercial
    GIREDESTRANT; TRASTUZUMAB, PERTUZUMAB
    2022-500014-26-00 8 countries 2022 n=218
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE
    2023-503568-18-00 14 countries 2021 n=377
    Ended
  • F. Hoffmann-La Roche AG Commercial
    PERTUZUMAB; TRASTUZUMAB
    2023-505102-42-00 3 countries 2014 n=23
    Ended
  • Greenwich LifeSciences Inc. Commercial
    L-ISOLEUCYL-L-ISOLEUCYL-L-SERYL-L-ALANYL-L-VALYL-L-VALYL-GLYCYL-L-ISOLEUCYL-L-LEUCINE; SARGRAMOSTIM
    2023-504323-25-01 10 countries 2024 n=435
    Recruiting
  • Roche Farma S.A. Commercial
    PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB, PERTUZUMAB
    2023-509321-50-00 1 country 2021 n=34
    Recruiting
  • Seagen Inc. Commercial
    TRASTUZUMAB, PERTUZUMAB; TUCATINIB
    2023-503826-37-00 12 countries 2022 n=249
    Ended
  • Fundacion Grupo Espanol De Investigacion En Cancer De Mama Academic
    IMP not specified
    2024-514611-98-00 1 country 2021 n=27
    Ended
  • Universitaetsklinikum Ulm AöR Academic
    TRASTUZUMAB DERUXTECAN
    2024-516173-76-01 1 country 2025 n=180
    Recruiting

Phase II/III

1 trial
  • F. Hoffmann-La Roche AG Commercial
    (R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE
    2025-524498-17-00 11 countries 2026 n=237
    Recruiting

Phase II

12 trials
  • Eisai Limited Commercial
    HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 CONJUGATED TO ERIBULIN
    2023-506866-30-00 3 countries 2024 n=45
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; PERTUZUMAB; TRASTUZUMAB EMTANSINE
    2023-503479-79-00 5 countries 2011 n=60
    Recruiting
  • Medica Scientia Innovation Research S.L. Commercial
    TRASTUZUMAB, PERTUZUMAB
    2023-508738-32-00 4 countries 2021 n=396
    Ended
  • Medica Scientia Innovation Research S.L. Commercial
    CARBOPLATIN; DOCETAXEL; LETROZOLE; PERTUZUMAB; TAMOXIFEN CITRATE; TRASTUZUMAB
    2023-509923-42-00 5 countries 2017 n=345
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    IMP not specified
    2024-514458-61-01 1 country 2024 n=705
    Ended
  • Fundacion Grupo Espanol De Investigacion En Cancer De Mama Academic
    LOPERAMIDE HYDROCHLORIDE
    2024-514630-21-00 4 countries 2022 n=175
    Ended
  • Grupo Espanol De Investigacion En Cancer De Ovario Academic
    TRASTUZUMAB DERUXTECAN
    2023-503627-26-00 1 country 2023 n=41
    Ended
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic
    TRASTUZUMAB DERUXTECAN
    2023-505039-11-00 5 countries 2024 n=112
    Recruiting
  • Institut Gustave Roussy Academic
    ATEZOLIZUMAB; BEVACIZUMAB; PERTUZUMAB; TRASTUZUMAB
    2024-512826-26-00 1 country 2022 n=185
    Ended
  • Institut Jules Bordet Academic
    TRASTUZUMAB; TRASTUZUMAB CONJUGATED TO N-SUCCINYLDESFERRIOXAMINE B-TETRAFLUORPHENOL AND RADIOLABELED WITH ZIRCONIUM (89ZR)
    2024-516253-49-00 1 country n=31
    Not authorised
  • Institut Jules Bordet Academic
    TRASTUZUMAB; TRASTUZUMAB CONJUGATED TO N-SUCCINYLDESFERRIOXAMINE B-TETRAFLUORPHENOL AND RADIOLABELED WITH ZIRCONIUM (89ZR)
    2024-516253-49-01 2 countries 2025 n=109
    Recruiting
  • Karolinska University Hospital Academic
    APREPITANT; BETAMETHASONE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN HYDROCHLORIDE; FILGRASTIM; GOSERELIN; LETROZOLE; METOCLOPRAMIDE HYDROCHLORIDE ANHYDROUS; OLANZAPINE; ONDANSETRON; PACLITAXEL; PALONOSETRON HYDROCHLORIDE; PEGFILGRASTIM; PERTUZUMAB; RIBOCICLIB; TRASTUZUMAB; TRASTUZUMAB DERUXTECAN; TRASTUZUMAB, PERTUZUMAB
    2022-501504-95-00 3 countries 2023 n=402
    Recruiting

Phase I/II

6 trials
  • Cyclacel Limited Commercial
    FADRACICLIB
    2024-516289-12-00 1 country 2022 n=30
    Ended
  • Enliven Therapeutics Inc. Commercial
    CAPECITABINE; ELVN-002-1; ERIBULIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB
    2023-509716-29-00 5 countries 2024 n=156
    Ended
  • Seagen Inc. Commercial
    DISITAMAB VEDOTIN; TUCATINIB
    2023-507555-29-00 4 countries 2024 n=68
    Recruiting
  • Centre Henri Becquerel Academic
    68GA-NOTA-ABSCINT-HER2
    2025-523286-23-00 1 country n=42
    Pending
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic
    PERTUZUMAB; TRASTUZUMAB
    2024-518192-61-00 1 country 2023 n=30
    Recruiting
  • Medica Scientia Innovation Research S.L. Academic
    CAPECITABINE; DEXAMETHASONE SODIUM PHOSPHATE; DIPHENHYDRAMINE HYDROCHLORIDE; ERIBULIN MESYLATE; HYDROCORTISONE SODIUM SUCCINATE; LOPERAMIDE HYDROCHLORIDE; PARACETAMOL; TUCATINIB
    2025-524613-89-00 1 country n=129
    Pending

Phase III/IV

1 trial
  • AstraZeneca AB Commercial
    TRASTUZUMAB DERUXTECAN
    2024-510588-53-00 8 countries 2021 n=482
    Ended

Phase I

5 trials
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    IMP not specified
    2023-503965-48-00 3 countries 2024 n=36
    Recruiting
  • Expres2ion Biotechnologies ApS Commercial
    IMP not specified
    2024-516333-12-00 1 country 2024 n=40
    Recruiting
  • Fusion Pharmaceuticals Inc. Commercial
    IMP not specified
    2025-521235-37-00 1 country n=45
    Ended

Phase I (Other)

3 trials
  • Pfizer Inc. Commercial
    IMP not specified
    2023-505881-27-00 1 country 2023 n=12
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-518696-65-00 1 country 2025 n=9
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2025-521924-31-00 1 country 2025 n=12
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 5 Phase II/III, Phase II, Phase III 2
Daiichi Sankyo Inc. Commercial 4 Phase I, Phase III 2
Pfizer Inc. Commercial 3 Phase I (Other) 0
Medica Scientia Innovation Research S.L. Commercial 3 Phase II, Phase I/II 0
Seagen Inc. Commercial 2 Phase III, Phase I/II 1
Fundacion Grupo Espanol De Investigacion En Cancer De Mama Academic 2 Phase II, Phase III 0
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic 2 Phase II, Phase I/II 2
Institut Jules Bordet Academic 2 Phase II 1
Beigene Ltd. Commercial 1 Phase I 0
BeOne Medicines AG Commercial 1 Phase I 1
Expres2ion Biotechnologies ApS Commercial 1 Phase I 1
Fusion Pharmaceuticals Inc. Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase III/IV 0
Eisai Limited Commercial 1 Phase II 0
WSG Westdeutsche Studiengruppe GmbH Commercial 1 Phase II 0
Aprogen Inc. Commercial 1 Phase III 0
Greenwich LifeSciences Inc. Commercial 1 Phase III 1
Roche Farma S.A. Commercial 1 Phase III 1
Cyclacel Limited Commercial 1 Phase I/II 0
Enliven Therapeutics Inc. Commercial 1 Phase I/II 0
New trials by year
2019
1
2021
6
2022
5
2023
4
2024
11
2025
4
2026
1
← All indication landscapes